Roth Capital Starts Obagi Medical Products (OMPI) at Buy
More News related to OMPI
- Obagi Medical Products (OMPI) Appoints Preston Romm to CFO Position
- Obagi Medical Products Names Preston Romm Chief Financial Officer
- Matrix USA Rating Changes 6/18
- Journal of Drugs in Dermatology Highlights Data Showing the Benefits of Solubilized 5% Benzoyl Peroxide Gel in the Treatment of Acne
- Roth Capital Starts Obagi Medical Products (OMPI) at Buy
Roth Capital initiates coverage on Obagi Medical Products, Inc. (Nasdaq: OMPI) with a Buy rating and $14 price target.
Obagi Medical Products, Inc., a specialty pharmaceutical company, develops and markets skincare products in the United States and internationally.
Related Categories
New CoverageStocks Mentioned
+0.15Related Entities
Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
